This site is intended for healthcare professionals only
LoginRegister
GSK, Pfizer ready to launch RSV vaccines for older adults in USGSK, Pfizer ready to launch RSV vaccines for older adults in US
Moderna COVID-19 vaccine linked to more delayed cutaneous reactionsModerna COVID-19 vaccine linked to more delayed cutaneous reactions
USFDA approves intramuscular administration for Merck’s MMRV Family of Vaccines: M-M-RII, VARIVAX, ProQuadUSFDA approves intramuscular administration for Merck’s MMRV Family of Vaccines: M-M-RII, VARIVAX,...
SEC Approves Serums Salk Polio Vaccine for Commercial Use, Recommends Phase I Trial for 21-valent Pneumococcal VaccineRevise Phase II/III CT protocol of Yellow Fever Vaccine Live: CDSCO Panel Tells Serum Institute of...
Health Ministry gets Porter Prize 2023 for COVID-19 managementHealth Ministry gets Porter Prize 2023 for COVID-19 management
Pfizers Abrocitinib Phase III Data Accepted by CDSCO Expert CommitteePfizer, BioNTech submit application to USFDA for emergency use nod of Omicron BA.4/BA.5-adapted...
Respiratory Syncytial virus vaccine effective in older adults, finds NEJM studyRespiratory Syncytial virus vaccine effective in older adults, finds NEJM study
Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic DermatitisPfizer RSV vaccine for elderly linked to Guillain-Barre risk, says USFDA
Wockhardt plans to roll out two vaccines within year from UK facility as part of a tie-up with SIIWockhardt plans to roll out two vaccines within year from UK facility as part of a tie-up with SII
Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic DermatitisPfizer, BioNTech seek USFDA nod for Omicron BA.4/BA.5-Adapted Bivalent COVID vaccine for ages 12...
Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic DermatitisPfizer Respiratory Syncytial Virus Maternal Vaccine candidate gets USFDA priority review
Moderna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in combination with KEYTRUDA to treat high risk melanomaModerna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in...
X